publication date: Jun. 9, 2017

Drugs and Targets BMS, Novartis announce collaboration focused on metastatic colorectal cancer

Bristol-Myers Squibb and Novartis announced a clinical research collaboration to investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).

The study, which will be conducted by BMS, is aimed at establishing recommended dose regimens and the preliminary anti-tumor activity of the combination therapies. Both BMS and Novartis will evaluate the results to determine optimal approaches and potential clinical development of these combinations.

Mekinist is a kinase inhibitor indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.

 

Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients

FDA approved the Ventana ALK CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer patients eligible for treatment with the Novartis drug Zykadia (ceritinib).

The Ventana ALK (D5F3) Assay is the only immunohistochemistry test approved by the FDA as a companion diagnostic for ZYKADIA.

The assay is sponsored by Roche.

The Ventana ALK CDx Assay is available for use on … Continue reading BMS, Novartis announce collaboration focused on metastatic colorectal cancer

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.